Lercanidipine: short plasma half-life, long duration of action and high cholesterol tolerance. Updated molecular model to rationalize its pharmacokinetic properties
LEOG HERBETTE, M VECCHIARELLI… - Blood …, 1998 - Taylor & Francis
Calcium-channel antagonist drugs of the 1, 4-dihydropyridine type have been shown to bind
to the L-type calcium channel. These drugs are not only amphiphilic, but new molecular …
to the L-type calcium channel. These drugs are not only amphiphilic, but new molecular …
Lacidipine: a review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of hypertension
C Rhoda Lee, HM Bryson - Drugs, 1994 - Springer
Synopsis Lacidipine is an orally administered calcium channel blocker of the
dihydropyridine class, which shows selectivity for vascular smooth muscle over cardiac …
dihydropyridine class, which shows selectivity for vascular smooth muscle over cardiac …
Lercanidipine: Short plasma half-life, long duration of action: a molecular model to rationalize its pharmacokinetic properties
LG Herbette, M Vecchiarelli… - Journal of Cardiovascular …, 1997 - journals.lww.com
Calcium-channel antagonist drugs of the 1, 4-dihydropyridine (DHP) type bind to the L-type
calcium channel. Not only are these drugs amphiphilic, but new molecular designs have …
calcium channel. Not only are these drugs amphiphilic, but new molecular designs have …
Effect of amlodipine on systolic blood pressure
CB Levine, KR Fahrbach, D Frame, JE Connelly… - Clinical …, 2003 - Elsevier
Background: Systolic hypertension is the most common form of hypertension, particularly in
people aged> 60 years. Caused by decreased compliance of large arteries, systolic …
people aged> 60 years. Caused by decreased compliance of large arteries, systolic …
Ramipril/amlodipine single pill—Effectiveness, tolerance and patient satisfaction with antihypertensive therapy in relation to nutritional status
M Olszanecka-Glinianowicz, M Smertka… - Pharmacological …, 2014 - Springer
Background Overweight and obesity decrease the effectiveness of antihypertensive therapy
despite the more frequent use of polytherapy. One method for improving therapy …
despite the more frequent use of polytherapy. One method for improving therapy …
Ankle edema formation during treatment with the calcium channel blockers lacidipine and amlodipine: a single-centre study
MB Andrésdóttir, HW van Hamersvelt… - Journal of …, 2000 - journals.lww.com
All studies suggesting a lower incidence of edema on lacidipine than on amlodipine are
based on subjective scoring. Therefore, we have compared edema formation on two …
based on subjective scoring. Therefore, we have compared edema formation on two …
Relative efficacy and tolerability of lacidipine and amlodipine in patients with mild-to-moderate hypertension: a randomized double-blind study
CP Lau, BMY Cheung - Journal of cardiovascular pharmacology, 1996 - journals.lww.com
Calcium channel blockers are increasingly used in the treatment of hypertension. Newer
calcium channel blockers of the dihydropyridine group have longer elimination half-lives …
calcium channel blockers of the dihydropyridine group have longer elimination half-lives …
Membrane pathways for drug/ion channel interactions: molecular basis for pharmacokinetic properties
LG Herbette - Drug development research, 1994 - Wiley Online Library
This review focuses on the interactions of certain classes of drugs that are known to bind to
membrane‐bound ion channel/receptors. The concepts described here have broad …
membrane‐bound ion channel/receptors. The concepts described here have broad …
Treatment effect of lacidipine and amlodipine on clinic and ambulatory blood pressure and arteria stiffness in a randomised double-blind trial
Y Wang, Y Li, Y Huo, JG Wang - Blood Pressure, 2021 - Taylor & Francis
Purpose In a randomised, double-blind trial, we investigated effects of lacidipine on clinic
and ambulatory blood pressure (BP) and arterial stiffness in patients with mild-to-moderate …
and ambulatory blood pressure (BP) and arterial stiffness in patients with mild-to-moderate …